Summary
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.
History
Gracell Biotechnologies was founded in 2019 by a group of leading scientists and entrepreneurs committed to making cell therapy more accessible and affordable. We quickly gained traction in the industry with our state-of-the-art cell therapy laboratories. Our high quality products and services have made us a trusted partner for scientists, clinicians and innovators all over the world.
Mission
To harness the power of cell therapy to empower people to heal and extend life.
Vision
We strive to be a leader in innovative cell therapy solutions that improve patient outcomes and enhance quality of life.
Key Team
Dr. Samuel Suhua Zhang M.B.A., Ph.D. (Chief Bus. Officer)
Dr. Wendy Li M.D. (Chief Medical Officer)
Ms. Erin Li (Exec. Officer)
Recognition and Awards
In 2020, Gracell Biotechnologies was awarded the 'Innovator of the Year' award from the China Chamber of Commerce for Innovative Science and Technology for its groundbreaking cell therapy technology.
References
